Castration-resistant prostate cancer

English BC, Baum CE, Adelberg DE et al (2010) A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Ther Clin Risk Manag 6 579-583... [Pg.669]

Scher, H.I. and Sawyers, C.L. (2005) Biology of progressive, castration-resistant prostate cancer directed therapies targeting the androgen-receptor signaling axis. Journal of Clinical Oncology, 23, 8253-8261. [Pg.292]

Madan RA et al. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res 2008 14 4526 531. [Pg.398]

Gioeli D, Wuderlich W, Sebolt-Leopold J, Bekiranov S, Wulfkufle JD, Petricoin EF 3rd, Conaway M, Weber MJ. Compensatory pathways induced by MEK inhibition are effective drag targets for combination therapy against castration-resistant prostate cancer. Mol Cancer Ther. 2011 10 1581-90. [Pg.712]

Nordin A, Wang W, Welen K, Damber JE. Midkine is associated with neuroendocrine differentiation in castration-resistant prostate cancer. Prostate. 2012 doi 10.1002/pros. 22607. [Pg.766]

Ishteiwy RA, Ward TM, Dykxhoom DM, Bumstein KL. The microRNA-23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cell. PLoS One. 2012 7(12)e52106. doi 10.1371/joumal.pone.0052106. [Pg.775]

Abiraterone acetate 117 is an androgen biosynthesis inhibitor, which was developed by the Institute of Cancer Research in the UK and further developed by Janssen for the oral treatment of patients with metastatic castration-resistant prostate cancer [75]. Its synthesis is relatively easy through a Suzuki coupling between the 17-enol triflate derived from the 3-acetate of dehydro-epiandrosterone (115) and 3-pyridyl-diethylborane (116) (Scheme 27) [76]. The reaction is catalysed by PdCl2(PPh3)2 and proceeds in good yield (84%). A similar Suzuki-based route in which the ketone starting material was converted into an alkenyliodide has also been published [77]. [Pg.20]

Enzalutamide (1, marketed as Xtandi and formerly known as MDV3100) was developed by the pharmaceutical company Medivation and was approved by the US FDA on August 31, 2012, for men with docetaxel-pretreated, metastatic castration-resistant prostate cancer (CRPC). The current market price for enzalutamide treatment is approximately 7000/month with treatments lasting 5-8 months. [Pg.103]

In phase I/II trials for enzalutamide 1, 140 men with progressive castration-resistant prostate cancer (CRPC) were enrolled across the United States. In a majority of those enrolled, the cancer was metastasized, and approximately half of the patients had received prior chemotherapy. Anti-tumor activity was observed at all doses and the maximum tolerated dose of enzalutamide was determined to be 240 mg daily, and no additional anti-tumor effects were... [Pg.109]

Ang JE, Olmos D, de Bono JS (2009) CYP17 blockade by abiraterone further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer 100 671-675... [Pg.257]

NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Deamaley D, Kheoh T, Molina A, de Bono JS (2009) Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27 3742 3748... [Pg.257]

LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de Bono JS (2010) Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 28 1489-1495... [Pg.257]

Shah S, Ryan C (2010) Abiraterone acetate for castration resistant prostate cancer. Exp Opin Invest Drugs 19 563 570... [Pg.257]

Yang LP (2011) Abiraterone acetate in metastatic castration-resistant prostate cancer. Drugs 71 2067-2077... [Pg.257]

Rehman Y, Rosenberg JE (2012) Abiraterone acetate oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drag Des Devel Ther 6 13-18... [Pg.257]

One interest in inhibition of P450 17A1 is treating prostate cancer. The corrcept is that prostate cancer is stimulated by androgerrs, and the goal is to block production of androstenedione (from progesterone/17a-hydroxyprogesterone). This is a particular issue in castration-resistant prostate cancer. [Pg.645]

Di Lorenzo G, Ferro M, Buonerba C (2012) Sip-uleucel-T (Provenge(R)) for castration-resistant prostate cancer. BJU Int 110 E99-104... [Pg.763]

Ross SA (2015) A multipUcity of targets evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes. Curr MedRes Opin 31 125-135 RovieUo G, Sigala S, Danes R et al (2016) Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors a meta-analysis of published trials. Crit Rev Oncol Hematol 101 12-20 Sankoh AJ, Li H, D Agostino RB Sr (2016) Use of composite endpoints in cUnical trials. Stat Med 35 319-320... [Pg.132]

Keizman D, Huang P, Carducci MA, Eisenberger MA. Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer clinical factors associated with PSA response and disease progression. Prostate 2012 72(4) 461-7. [Pg.389]

Enzalutamide is an oral inhibitor of AR signalling that blocks AR interaction, inhibits translocation of the AR to the nucleus, impairs AR binding to DNA and inhibits co-activator recruitment and receptor-mediated DNA transcription. In the United Kingdom, enzalutamide is licensed for the treatment of men wi metastatic, castrate-resistant prostate cancer whose disease has progressed on or after docetaxel-based chemotherapy. [Pg.629]

Hoffman-Censits J, Kelly WK. Enzalutamide a novel antiandrogen for patients with castrate-resistant prostate cancer. Clin Cancer Res 2013 19(6) 1335-9. [Pg.634]

Chi KN, Hotte SJ, Yu EY et al (2010) Randomized phase II study of docetaxel and prednisone with ot without OGX-OII in patients with metastatic castration-resistant prostate cancer. J Qin Oncol 28 4247-4254... [Pg.176]

British Columbia Cancer Agency (2010) OGX-427 in castration resistant prostate cancer patients. Available at http //clinicaltrials.gov/ct2/show/NCT01120470. Last accessed 25 July 2011. US National Library of Medicine, Bethesda... [Pg.176]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...